{"id":"vehicle-placebo-nasal-spray","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=vehicle placebo nasal spray","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:09:12.720730+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:09:18.295150+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vehicle placebo nasal spray","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:09:18.726630+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108661/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:09:19.478478+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vehicle placebos are used in clinical research as control comparators to isolate the true pharmacological effects of an active drug from placebo effects and natural disease progression. This particular formulation is a nasal spray vehicle—likely containing saline, buffering agents, and preservatives—without any therapeutic agent, allowing researchers to measure the efficacy of the actual drug being tested.","oneSentence":"A vehicle placebo nasal spray contains no active pharmaceutical ingredient and serves as an inert control formulation for clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:00.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:09:21.056819+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Clinical trial control/comparator (not a therapeutic product)"}]},"trialDetails":[{"nctId":"NCT07259538","phase":"PHASE1","title":"A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray","status":"RECRUITING","sponsor":"VivaVision Biotech, Inc","startDate":"2025-11-06","conditions":"Chronic Rhinosinusitis (CRS)","enrollment":60},{"nctId":"NCT07146126","phase":"PHASE3","title":"A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Prime Gene Therapeutics Co., Ltd.","startDate":"2025-09-15","conditions":"Seasonal Allergic Rhinitis, SAR","enrollment":600},{"nctId":"NCT06837233","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prime Gene Therapeutics Co., Ltd.","startDate":"2025-03-12","conditions":"Seasonal Allergic Rhinitis","enrollment":160},{"nctId":"NCT04957758","phase":"PHASE2","title":"Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2021-06-17","conditions":"Neurotrophic Keratopathy","enrollment":113},{"nctId":"NCT05180500","phase":"PHASE1","title":"Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis","status":"COMPLETED","sponsor":"Sharon Hillier","startDate":"2022-03-15","conditions":"COVID-19, Pharmacokinetics, Safety","enrollment":50},{"nctId":"NCT06126952","phase":"PHASE2","title":"Azelastine Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2023-10-30","conditions":"Seasonal Allergic Rhinitis","enrollment":84},{"nctId":"NCT06106880","phase":"PHASE1","title":"Alleviation of Common Cold Symptoms","status":"COMPLETED","sponsor":"Applied Biological Laboratories Inc","startDate":"2022-05-25","conditions":"Common Cold, Pharyngitis, Fever","enrollment":157},{"nctId":"NCT03920215","phase":"PHASE2, PHASE3","title":"Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2018-08-15","conditions":"Long Term Follow up Dry Eye Disease","enrollment":101},{"nctId":"NCT05082974","phase":"PHASE3","title":"Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)","status":"COMPLETED","sponsor":"Vance Thompson Vision ND","startDate":"2021-10-20","conditions":"Dry Eye Disease","enrollment":40},{"nctId":"NCT05378945","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2022-07-22","conditions":"Dry Eye Disease","enrollment":340},{"nctId":"NCT04652245","phase":"PHASE4","title":"Dymista Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2020-12-14","conditions":"Seasonal Allergic Rhinitis","enrollment":216},{"nctId":"NCT05161208","phase":"PHASE4","title":"OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers","status":"COMPLETED","sponsor":"Center for Ophthalmic and Vision Research, LLC","startDate":"2021-12-03","conditions":"Dry Eye","enrollment":75},{"nctId":"NCT05514041","phase":"PHASE4","title":"A Randomized, Controlled, Double-masked, Investigator-initiated Trial to Evaluate Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray","status":"UNKNOWN","sponsor":"Stephenson Eye Associates","startDate":"2022-08-29","conditions":"Dry Eye Disease","enrollment":60},{"nctId":"NCT03873246","phase":"PHASE2","title":"Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2019-02-18","conditions":"Dry Eye Disease","enrollment":123},{"nctId":"NCT03633461","phase":"PHASE2","title":"Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2018-08-14","conditions":"Dry Eye Disease","enrollment":53},{"nctId":"NCT03688802","phase":"PHASE2","title":"Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2018-09-25","conditions":"Dry Eye Disease","enrollment":18},{"nctId":"NCT03452397","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2018-02-27","conditions":"Dry Eye Disease","enrollment":165},{"nctId":"NCT05136924","phase":"PHASE2","title":"IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL","status":"UNKNOWN","sponsor":"Vance Thompson Vision - MT","startDate":"2021-12-01","conditions":"Dry Eye Disease","enrollment":20},{"nctId":"NCT04036292","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2019-07-23","conditions":"Dry Eye Disease (DED)","enrollment":758},{"nctId":"NCT03636061","phase":"PHASE2","title":"Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Oyster Point Pharma, Inc.","startDate":"2018-08-15","conditions":"Dry Eye Disease","enrollment":182},{"nctId":"NCT01673659","phase":"PHASE3","title":"A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2012-08","conditions":"Seasonal Allergic Rhinitis","enrollment":1220},{"nctId":"NCT05045508","phase":"PHASE3","title":"Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)","status":"UNKNOWN","sponsor":"Brandon Baartman","startDate":"2021-08-30","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT04576312","phase":"PHASE1","title":"Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers","status":"COMPLETED","sponsor":"UNION therapeutics","startDate":"2020-06-29","conditions":"Covid19","enrollment":64},{"nctId":"NCT02025725","phase":"PHASE3","title":"Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis","status":"COMPLETED","sponsor":"Evoke Pharma","startDate":"2014-03-27","conditions":"Diabetic Gastroparesis","enrollment":205},{"nctId":"NCT02025751","phase":"PHASE3","title":"Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis","status":"COMPLETED","sponsor":"Evoke Pharma","startDate":"2014-04","conditions":"Diabetic Gastroparesis","enrollment":53},{"nctId":"NCT04306354","phase":"PHASE1, PHASE2","title":"Use of Intranasal Oxytocin During Detoxification of Crack Cocaine","status":"UNKNOWN","sponsor":"Pontificia Universidade Católica do Rio Grande do Sul","startDate":"2018-09-15","conditions":"Cocaine Withdrawal, Cocaine Smoking, Cocaine-Related Disorders","enrollment":96},{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT03005067","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-29","conditions":"Common Cold","enrollment":171},{"nctId":"NCT01013701","phase":"PHASE4","title":"Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Patients With Nasal Polyps","enrollment":7},{"nctId":"NCT01231464","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Rhinitis, Allergic, Perennial, Allergic Rhinitis","enrollment":365},{"nctId":"NCT02832362","phase":"PHASE1","title":"Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-11","conditions":"Common Cold","enrollment":30},{"nctId":"NCT01886313","phase":"PHASE2","title":"Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve","status":"TERMINATED","sponsor":"Winston Laboratories","startDate":"2014-03","conditions":"Postherpetic Neuralgia","enrollment":11},{"nctId":"NCT00682643","phase":"PHASE4","title":"A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06","conditions":"Rhinitis, Allergic, Perennial","enrollment":550},{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725},{"nctId":"NCT00716807","phase":"NA","title":"Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-01","conditions":"Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome","enrollment":46},{"nctId":"NCT01915823","phase":"PHASE3","title":"Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Meda Pharmaceuticals","startDate":"2013-07","conditions":"Seasonal Allergic Rhinitis","enrollment":348},{"nctId":"NCT01817790","phase":"PHASE3","title":"Assessment of Fluticasone Propionate on Ocular Allergy Symptoms","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12","conditions":"Allergic Rhinitis, Seasonal Allergic Rhinitis","enrollment":626},{"nctId":"NCT01454505","phase":"PHASE1","title":"Safety and Efficacy of AL-53817 Nasal Spray Solution","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-10","conditions":"Nasal Allergies, Allergies","enrollment":110},{"nctId":"NCT01134705","phase":"PHASE3","title":"Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-05","conditions":"Rhinitis, Allergic, Perennial","enrollment":474},{"nctId":"NCT00854360","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-03","conditions":"Seasonal Allergic Rhinitis, Hayfever","enrollment":487}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2108661"},"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"vehicle placebo nasal spray","genericName":"vehicle placebo nasal spray","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A vehicle placebo nasal spray contains no active pharmaceutical ingredient and serves as an inert control formulation for clinical trials. Used for Clinical trial control/comparator (not a therapeutic product).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:09:21.056819+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}